Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-Fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-Fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer

X
Trial Profile

A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-Fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-Fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PRIME
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2022 Results (n=461) of an analysis assessing predictive score to identify patients who are likely to benefit from Panitumumab treatment between differential variables subgroups using data from three clinical studies: NCT00364013, NCT00339183 and NCT00113763 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 13 Apr 2022 Results of an analysis (n=328) assessed the tumor heterogeneity in response to therapy presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 13 Apr 2022 Results (n=935) assessing age related disparity in treatment outcome and adverse events among patients with metastatic colorectal cancer using patient data from this trial presented at the 113th Annual Meeting of the American Association for Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top